Meeting Banner
Abstract #1364

Assessment of Anti-EGFRvIII Chimeric Antigen Receptor (CAR) T cell Therapy for Patients with Glioblastomas using Diffusion, Perfusion and MR Spectroscopy

Sumei Wang1, Donald M O’Rourke2, Sanjeev Chawla1, Gaurav Verma1, Gabriela Plesa3, Carl H June3, Marcela V Maus4, Steven Brem2, Eileen Maloney2, Jennifer JD Morrissette5, Maria Martinez-Lage5, Arati Desai6, Ronald L Wolf1, Harish Poptani1,7, and Suyash Mohan1

1Radiology, University of Pennsylvania, Philadelphia, PA, United States, 2Neurosurgery, University of Pennsylvania, Philadelphia, PA, United States, 3Pathology and Laboratory Medicine, Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, PA, United States, 4Center for Cancer Immunology, Massachusetts General Hospital Cancer Center, Charlestown, MA, United States, 5Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, United States, 6Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, United States, 7Cellular and Molecular Physiology, University of Liverpool, Liverpool, United Kingdom

Chimeric Antigen Receptor (CAR) T cell therapy is a novel method of treating tumors. Since EGFRvIII is expressed in some glioblastomas, we evaluated the efficacy of anti-EGFRvIII CART for treating these tumors. Treatment response was assessed via serial MRI scans at 1 and 2 months after CAR-T cell therapy. The rCBVmax and Cho/Cr ratio decreased whereas MD and FA stayed relatively stable for most patients, indicating a positive response that can be assessed by these methods.

This abstract and the presentation materials are available to members only; a login is required.

Join Here